PureTech Health PLC (PRTC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, PureTech Health PLC (PRTC) has a cash flow conversion efficiency ratio of -0.126x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-38.47 Million) by net assets ($305.68 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how many days can PureTech Health PLC fund operations to measure how many days the company can operate on defensive assets alone.
PureTech Health PLC - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how PureTech Health PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data.
PureTech Health PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of PureTech Health PLC ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Apex International Co Ltd
TW:4927
|
0.007x |
|
Crescent Capital BDC Inc
NASDAQ:CCAP
|
0.022x |
|
Jay Mart Public Company Limited
BK:JMART
|
0.025x |
|
Gorilla Technology Group Inc.
NASDAQ:GRRR
|
-0.069x |
|
Universal Logistics Holdings Inc
NASDAQ:ULH
|
0.045x |
|
Apartment Investment and Management Co
NYSE:AIV
|
0.005x |
|
AQUILA PART PROD COM
RO:AQ
|
0.061x |
|
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A
SHE:002864
|
0.016x |
Annual Cash Flow Conversion Efficiency for PureTech Health PLC (2012–2025)
The table below shows the annual cash flow conversion efficiency of PureTech Health PLC from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see market value of PureTech Health PLC.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $305.68 Million | $-85.33 Million | -0.279x | +15.25% |
| 2024-12-31 | $407.93 Million | $-134.37 Million | -0.329x | -42.50% |
| 2023-12-31 | $458.23 Million | $-105.92 Million | -0.231x | +29.21% |
| 2022-12-31 | $547.59 Million | $-178.79 Million | -0.327x | -20.51% |
| 2021-12-31 | $584.15 Million | $-158.27 Million | -0.271x | -34.32% |
| 2020-12-31 | $653.54 Million | $-131.83 Million | -0.202x | -33.66% |
| 2019-12-31 | $650.40 Million | $-98.16 Million | -0.151x | +65.38% |
| 2018-12-31 | $166.97 Million | $-72.80 Million | -0.436x | +68.54% |
| 2017-12-31 | $64.00 Million | $-88.69 Million | -1.386x | -120.68% |
| 2016-12-31 | $92.41 Million | $-58.03 Million | -0.628x | -260.08% |
| 2015-12-31 | $164.05 Million | $-28.61 Million | -0.174x | -121.14% |
| 2014-12-31 | $133.69 Million | $-10.54 Million | -0.079x | -107.21% |
| 2013-12-31 | $-8.03 Million | $-8.77 Million | 1.093x | +152.49% |
| 2012-12-31 | $-3.35 Million | $-1.45 Million | 0.433x | -- |
About PureTech Health PLC
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. The co… Read more